Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000041910 | SCV000065606 | benign | not specified | 2008-02-19 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000041910 | SCV000114882 | benign | not specified | 2013-04-05 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000041910 | SCV000169751 | benign | not specified | 2013-01-07 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Prevention |
RCV000041910 | SCV000317211 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV001513893 | SCV001721594 | benign | not provided | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001274240 | SCV001750320 | benign | Usher syndrome type 2A | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Dept Of Ophthalmology, |
RCV003888406 | SCV004707947 | benign | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Breakthrough Genomics, |
RCV001513893 | SCV005280569 | benign | not provided | criteria provided, single submitter | not provided | ||
Natera, |
RCV001274240 | SCV001458120 | benign | Usher syndrome type 2A | 2020-09-16 | no assertion criteria provided | clinical testing |